

sequence of SEQ ID NO: 155;

(p) a bispecific antibody which comprises a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 123, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 135, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 145, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 156;

(q) a bispecific antibody which comprises a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 124, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 136, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 144, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 155;

(r) a bispecific antibody which comprises a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 124, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 136, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 146, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 157;

(s) a bispecific antibody which comprises a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 124, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 134, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 147, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 158;

(t) a bispecific antibody which comprises a first antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 125, a first antibody light chain comprising the amino acid sequence of SEQ ID NO: 137, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 148, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 159.

In yet another aspect, the present invention refers to an isolated nucleic acid which encodes the bispecific antibody of the present disclosure.

In yet another aspect, the present invention refers to a host cell which comprises the nucleic acid of the present disclosure.

In yet another aspect, the present invention refers to a pharmaceutical formulation which comprises the bispecific antibody of the present disclosure, and a pharmaceutically acceptable carrier.

In yet another aspect, the present invention refers to the pharmaceutical formulation of the present invention for use as a medicament.

In yet another aspect, the present invention refers to the use of the pharmaceutical formulation of the present invention in the manufacture of a medicament for the prevention and/or

treatment of bleeding, a disease involving bleeding, or a disease caused by bleeding, wherein the bleeding, the disease involving bleeding, or the disease caused by bleeding is a disease which develops and/or progresses due to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII.

- 5 The present disclosure has been made based on such findings, and specifically provides [1] to [25] below:
- [1] a multispecific antigen-binding molecule which has a function to substitute for the function of blood coagulation factor VIII, wherein the molecule comprises a first antigen-binding site

SEQ ID NO: 137, a second antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 148, and a second antibody light chain comprising the amino acid sequence of SEQ ID NO: 159.

- 5 4. An isolated nucleic acid which encodes the bispecific antibody of any one of claims 1-3.
5. A host cell which comprises the nucleic acid of claim 4.
6. A pharmaceutical formulation which comprises the bispecific antibody of any one of
10 claims 1-3, and a pharmaceutically acceptable carrier.
7. The pharmaceutical formulation of claim 6 for use as a medicament.
8. Use of the pharmaceutical formulation of claim 6 in the manufacture of a medicament
15 for the prevention and/or treatment of bleeding, a disease involving bleeding, or a disease caused
 by bleeding, wherein the bleeding, the disease involving bleeding, or the disease caused by
 bleeding is a disease which develops and/or progresses due to a decrease or deficiency in the
 activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII.
- 20 9. The use according to claim 8, wherein the disease which develops and/or progresses due
 to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood
 coagulation factor VIII is hemophilia A, a disease with emergence of an inhibitor against blood
 coagulation factor VIII and/or activated blood coagulation factor VIII, acquired hemophilia, or
 von Willebrand disease.